| abstract |
The present invention relates to the field of drug treatment of cognitive deficits in learning and memory by administering α-aminoamides, in particular sapinamide. Examples of cognitive disorders that can be treated with the compounds of the present invention are diseases such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorder, psychosis, mood swings, depressive disorder, Tourette syndrome, mild cognitive impairment (MCI) Learning disability, age-related memory impairment, age-related cognitive impairment, Alzheimer's disease, Parkinson's disease, Down's syndrome, traumatic brain injury Huntington's disease, progressive nuclear palsy (PSP), HIV, stroke, vascular disease in children, adolescents and adults , Diseases such as Pick's disease or Creutz-Felt Jacob disease, multiple sclerosis (MS), other white matter diseases, and diseases such as drug-induced cognitive deterioration. |